Beste apotheek van Nederland

sex with partner (scale 1–6, with = “none” and 6 = “full”), with a mean score of 5.5 for each
group, or in the degree of erection during masturbation.
In the third trial, 325 results were reported for the 52 men (70 percent) who completed the
treatment schedule. Within this group, 62.5 percent of men who received testosterone versus 20
percent of those who received placebo reported that their erectile function was much or very
much improved (RR = 3.12, 95 percent CI: 1.25–7.82).
In the fourth trial, 328 the difference in frequency (1 = less than 1 per month” and 2 = 1–2 per
month”) of full erections during one month between men in the IM testosterone and IM placebo
groups was not statistically significant (1.77 versus 1.53)
Testosterone (IM) versus human chorionic gonadotropin (IM). One trial compared the
efficacy and harms of IM testosterone versus IM human chorionic gonadotropin. 323 In this trial,
9 gonadotropin-deficient men aged 15 years or older (range 16–20) being treated for
hypopituitarism, were randomized to 1 cc IM testosterone enanthate given every 2 weeks versus
2000 units of human chorionic gonadotropin 3 times weekly versus placebo. The active
treatment arms each lasted for at least 6 months, while the placebo treatment lasted for 2 months.
Harms. No adverse event data were reported.
Efficacy. The weekly frequency of erection was not different between the two groups of
testosterone and human chorionic gonadotropin treatment (7.9 versus 8.2).
Gel testosterone versus placebo. The efficacy and harms of gel testosterone versus placebo
were compared in one trial 317 In this trial, 406 hypogonadal men (total T <300 ng/dL) aged 20–
80 years (mean age: 58 years) reporting one or more symptoms of low testosterone deficiency
(i.e. fatigue, decreased muscle mass, reduced libido), were randomized to 50 mg gel testosterone
(Testim) daily versus 100 mg gel testosterone (Testim) daily versus 24.4 mg patch testosterone
(Androderm) versus placebo.
Harms. In total, 29.3 percent of men receiving 50 mg gel testosterone; 36.8 percent receiving
100 mg gel testosterone and 40.4 percent receiving placebo reported at least one treatmentrelated
adverse event (including application site reactions, BPH, increase in blood pressure,
increase in hematocrit, gynecomastia, headache, hot flashes, insomnia, mood swings, or
spontaneous erections). These differences were not statistically significant. One participant from
the group treated with 50 mg gel testosterone, five in the group treated with 100 mg gel
testosterone, and none treated with placebo withdrew due to an adverse event.
Efficacy. At day 30, among men with sexual partners (63 percent of randomized men), 24
percent of placebo-treated men reported an increase from baseline in the number of days in the
past week with sexual intercourse, compared with 31 percent of 50 mg gel testosterone-treated
men (p <0.05 versus placebo) and 39 percent of 100 mg gel testosterone men (p = 0.0096 versus
placebo).
Gel testosterone versus patch testosterone. The efficacy and harms of gel testosterone
versus patch testosterone was compared in three trials. 317,320,327 In the first trial, 327 227 men aged
19-68 years (mean age: 58 years) with total testosterone levels <10.4 nmol/L (300 ng/dL) were
randomized to 50 mg gel testosterone (Androgel) given daily versus 100 mg gel testosterone
(Androgel) given daily versus 5 mg patch testosterone (Androderm) given daily. Patients with
increased PSA, significant skin disease, and substantial under- or overweight were excluded.
The other two trials 317,320 had similar protocols. The inclusion criteria were low total
testosterone (<10.4 nmol/l 320 and <300 ng/dL 317 ) and/or symptoms of hypogonadism (i.e. fatigue,
decreased muscle mass, reduced libido, or “reduced sexual functioning” of nonmechanical
95